12:00 AM
 | 
Dec 21, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tykerb lapatinib: Final Phase III data

Final data from an open-label, international Phase III trial in 296 patients with HER2-positive breast cancer who had progressed following previous treatment with Herceptin trastuzumab showed that Tykerb plus Herceptin significantly improved median OS vs. Tykerb alone...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >